Hovione has completed a $100 million investment to double spray-drying capacity and expand its East Windsor, New Jersey site, positioning the facility to meet growing US demand.
Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), today announced the second phase of an expansion strategy at its Deeside, UK site to support antibody-drug conjugate (ADC) development, with a more than £10 million (€11.9 million) investment to increase GMP bioconjugation capacity.
Navin Molecular, an Indian-headquartered CDMO with small molecule development and manufacturing capabilities, recently announced a Rs 288 Crore (approximately €32.6 million/$35 million) investment to construct a 9,000 m2 GMP manufacturing plant in Dewas, India. The new facility will nearly double the overall capacity at the site to 420 m3. It will support existing commercial-scale projects and meet future demands as the company continues to expand its global customer base.
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
